Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Autolus Therapeutics Plc ADR
(NQ:
AUTL
)
4.190
+0.080 (+1.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Autolus Therapeutics Plc ADR
< Previous
1
2
3
4
5
Next >
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
November 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
October 17, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Where Autolus Therapeutics Stands With Analysts
June 02, 2023
Via
Benzinga
Preview: Autolus Therapeutics's Earnings
May 03, 2023
Via
Benzinga
The Latest Analyst Ratings for Autolus Therapeutics
April 28, 2023
Via
Benzinga
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
October 11, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
October 11, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
September 05, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
August 17, 2023
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9
Via
Benzinga
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
August 03, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
July 19, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
July 18, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
July 06, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in Cancer Immunology Research
June 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
June 20, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
June 16, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
3 Top Penny Stock Picks You Haven’t Heard Of
June 14, 2023
Here are three penny stock picks investors likely haven't heard of, but probably should keep on the radar as speculative options.
Via
InvestorPlace
Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023
June 06, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
June 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL
May 22, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 15, 2023
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
May 15, 2023
Via
Benzinga
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA
May 12, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress
May 04, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
April 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
April 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
April 26, 2023
- Expanding the Autolus toolkit of T-cell engineering modules against complex and immunologically hostile cancers, including solid cancer applications
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
April 26, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Host Virtual Capital Markets Day
April 25, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.